Previous 10 |
home / stock / mpsyf / mpsyf news
The following slide deck was published by MorphoSys AG in conjunction with their 2019 Q3 earnings Read more ...
Morphosys Ag (MPSYF) Q2 2019 Earnings Conference Call August 6, 2019 08:00 ET Company Participants Sarah Fakih - Investor Relations Simon Moroney - Chief Executive Officer Jens Holstein - Chief Financial Officer Malte Peters - Chief Development Officer Conference Call Partic...
MorphoSys AG ( OTCPK:MPSYF ): Q2 GAAP EPS of -€0.19. More news on: MorphoSys AG, Earnings news and commentary, Healthcare stocks news, Read more ...
MorphoSys ( OTCPK:MPSYF ) announced the appointment of Jean-Paul Kress, M.D., as its new Chief Executive Officer, effective September 1, 2019. More news on: MorphoSys AG, MorphoSys AG, MorphoSys AG ADR, Healthcare stocks news, Read more ...
MorphoSys AG (MPSYF) Q1 2019 Earnings Conference Call May 08, 2019, 08:00 AM ET Company Participants Sarah Fakih - Head of Corporate Communications and IR Simon Moroney - CEO Jens Holstein - CFO Conference Call Participants James Gordon - JPMorgan Danielle Brill - Piper J...
The following slide deck was published by MorphoSys AG in conjunction with their 2019 Q1 earnings Read more ...
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 2, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; Nasdaq: MOR) will publish its first three months' 2019 results on May 7, 2019 at 10:00pm CEST (9:00pm BST; 4:00pm EDT). The Management team of MorphoSys AG will host a ...
The following slide deck was published by MorphoSys AG in conjunction with their 2018 Q4 earnings Read more ...
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / January 31, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) announced today that in its lawsuit against Janssen Biotech and Genmab A/S, the parties have settled the dispute. As a result of this, the parties to the ...
News, Short Squeeze, Breakout and More Instantly...
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 20, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG. Novartis BidCo Germany ...
Additional ASCO 2024 poster presentation will include new findings from the Phase 2 study of tulmimetostat PLANEGG and MUNICH, GERMANY / ACCESSWIRE / April 24, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that new efficacy and safety data from the Phase 3 MANIFEST-2 trial of pel...
Novartis offers € 68.00 per share in cash, representing a total equity value of € 2.7 billion Shareholders benefit from attractive premium of 94% and 142% on the volume-weighted average price during the last month and three months before January 25, 2024, respectively Acce...